MEK1/2 inhibitors and 17AAG synergize to kill human GI tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95

Prior studies have noted that inhibitors of MEK1/2 enhanced geldanamycin lethality in malignant hematopoietic cells by promoting mitochondrial dysfunction. The present studies focused on defining the mechanism(s) by which these agents altered survival in carcinoma cells. MEK1/2 inhibitors (PD184352;...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Park, Margaret A., Zhang, Guo, Mitchell, Clint, Rahmani, Mohamed, Hamed, Hossein, Hagan, Michael P., Yacoub, Adly, Curiel, David T., Fisher, Paul B., Grant, Steven, Dent, Paul
Format: Artigo
Idioma:Inglês
Publicat: 2008
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2585522/
https://ncbi.nlm.nih.gov/pubmed/18790746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-08-0400
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars